Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Nimotuzumab, and Toripalimab vs GP Induction in Nasopharyngeal Carcinoma
NCT06026878Phase 3Recruiting
- Sponsor
- Air Force Medical University
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nimotuzumab and toripalimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Air Force Medical University. Primary endpoint: Overall Response Rate. Started Sep 2023; status: recruiting.
02
Drugs
nimotuzumabtoripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06026878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026878.